Physician profile
Sondra D Verser
NPI 1245773605
$4,525.73
in general payments reported to CMS, 2019-2025
12 companies · $125 in 2025
The $125 reported for 2025 was less than what a typical Psychiatric/Mental Health (Nurse Practitioner) provider received nationally (typical 2025 total: $257).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $825 · 2022: $1,022 · 2023: $1,761 · 2024: $793 · 2025: $125.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,613 · Education: $65.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,612.75 |
| Education | $65.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $1,002.91 | 2022-2025 | Abilify Maintena, Rexulti, Abilify Asimtufii |
| Alkermes, INC. | $968.90 | 2021-2024 | Lybalvi, Aristada, Aristada Initio |
| Janssen Pharmaceuticals, INC | $809.30 | 2021-2023 | Invega Sustenna, Invega Trinza |
| Abbvie INC. | $325.75 | 2021-2024 | |
| Axsome Therapeutics, INC. | $308.39 | 2023-2024 | Auvelity |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $261.91 | 2022-2023 | |
| Neurocrine Biosciences, INC. | $256.63 | 2022-2023 | Ingrezza |
| Indivior INC. | $217.55 | 2022-2023 | Sublocade |
| Braeburn INC. | $130.00 | 2023 | Brixadi |
| Vanda Pharmaceuticals INC. | $110.88 | 2024 | Fanapt |
| Gilead Sciences, INC. | $97.79 | 2023 | Epclusa |
| Teva Pharmaceuticals USA, INC. | $35.72 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sondra Verser listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.